New Long-Acting HIV shot tested in healthy people
NCT ID NCT05112939
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study tested a long-acting injectable form of the HIV drug rilpivirine, alone or with another drug called cabotegravir, in 126 healthy adults. The goal was to see how the body processes the drugs and whether they are safe. This trial does not test treatment or prevention of HIV, but gathers important safety and dosing information for future studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- rilpivirine and cabotegravir long-acting injections
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
PRA Health Sciences
Groningen, NZ 9728, Netherlands
-
PRA Health Sciences 1
Salt Lake City, Utah, 84124, United States
-
PRA Health Sciences 2
Lenexa, Kansas, 66219, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief
- Could everyday disinfectants be harming us? a new study investigates
- Can a new drug keep the Heart's beat steady? trial puts verducatib to the test